Altamira Therapeutics (NASDAQ:CYTO) Trading 7.1% Higher

Altamira Therapeutics Ltd. (NASDAQ:CYTOGet Rating) traded up 7.1% on Thursday . The stock traded as high as $0.46 and last traded at $0.45. 325,331 shares changed hands during trading, a decline of 90% from the average session volume of 3,210,242 shares. The stock had previously closed at $0.42.

Altamira Therapeutics Stock Performance

The firm has a 50-day moving average of $0.58 and a two-hundred day moving average of $0.90.

Hedge Funds Weigh In On Altamira Therapeutics

A hedge fund recently raised its stake in Altamira Therapeutics stock. BlackRock Inc. boosted its position in shares of Altamira Therapeutics Ltd. (NASDAQ:CYTOGet Rating) by 84.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,603 shares of the company’s stock after acquiring an additional 28,151 shares during the period. BlackRock Inc. owned approximately 0.41% of Altamira Therapeutics worth $67,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 3.80% of the company’s stock.

About Altamira Therapeutics

(Get Rating)

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.

Featured Stories

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with's FREE daily email newsletter.